Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC

NCT04909684 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

750

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Pembrolizumab

Sponsor

Radboud University Medical Center

Collaborators

[object Object]